SLS-007 / UCLA, Seelos Therap - LARVOL DELTA

Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022 (PRNewswire) - “Seelos Therapeutics, Inc…released the itinerary for its research and development update conference call and webcast to be held on Thursday, December 15th from 1pm to 3pm ET….SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion): Raj Mehra, Ph.D. will provide an update of the ongoing registration directed studies of SLS-005 in amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). Jeffrey H. Kordower, Ph.D…will discuss recent developments Seelos has made with SLS-005 in Huntington's disease and Alzheimer's disease. SLS-004 and SLS-007 (gene therapy approaches for Parkinson's disease): Krishna Subramanian, Ph.D…will discuss recent data and Raj Mehra, Ph.D. will discuss next steps for the programs.”

Clinical • Clinical data • Trial status • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • Ataxia • CNS Disorders • Huntington's Disease • Parkinson's Disease

Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007 (PRNewswire) - "Seelos Therapeutics...announced it has received a Notice of Allowance for U.S. patent application number 16/833,515 from the United States Patent and Trademark Office (USPTO) covering SLS-007 titled: 'Structure-Based Peptide Inhibitors of Alpha-Synuclein Aggregation'....This Notice of Allowance covers the method of treating several neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease (PD), Lewy body dementia and multiple system atrophy, through contacting alpha-synuclein (α-synuclein) protofilaments with an effective amount of SLS-007. Seelos is currently delivering SLS-007 via an adeno-associated virus (AAV) in a preclinical study designed...Preliminary data from the study is expected in the second half of 2022."

Patent • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Multiple System Atrophy • Parkinson's Disease

Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007 (PRNewswire) - "Seelos Therapeutics, Inc...announced today that it has received an issued patent from the Japanese Patent Office...covering the composition of matter for SLS-007, a potentially disease-modifying gene therapy focused on intracellular alpha-synuclein (α-synuclein) aggregation in Parkinson's disease (PD). Seelos is currently conducting in vivo pre-clinical studies delivering SLS-007 via an adeno-associated virus (AAV) that is designed to target the non-amyloid component core (NACore) of α-synuclein to inhibit abnormal aggregation and accumulation of the α-synuclein protein in the brains of patients with Parkinson's Disease (PD). The preclinical studies are designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement parameters of SLS-007."

Patent • Preclinical • CNS Disorders • Parkinson's Disease

Seelos Therapeutics Announces Issuance of Composition of Matter Patent for SLS-007 (PRNewswire) - "Seelos Therapeutics, Inc....announced that it has been issued U.S. patent number 10815271 (application number 16/311,593) from the United States Patent and Trademark Office (USPTO) covering the composition of matter for SLS-007, a potentially disease-modifying gene therapy focused on intracellular alpha-synuclein (α-synuclein) aggregates in Parkinson's disease (PD)....The preclinical study is designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement parameters of SLS-007. Preliminary data from the study is currently expected in Q1 2021."

Patent • Preclinical • CNS Disorders • Parkinson's Disease

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson’s Disease (PRNewswire) - "Seelos Therapeutics, Inc....today announced the initiation of a preclinical study of SLS-007 in Parkinson's disease (PD) delivered through an adeno associated viral (AAV) vector targeting the non-amyloid component core (NACore) of alpha synuclein....Production of AAV1/2 vectors encoding each of the two novel peptides incorporating hemagglutinin (HA) tags has already been completed....Top-line data is currently expected in late 2020/early 2021."

PK/PD data • Preclinical • CNS Disorders • Parkinson's Disease

Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007 (GlobeNewswire, Seelos Therapeutics, Inc.) - "Seelos Therapeutics, Inc....today announced an update to its Parkinson’s Disease program SLS-007. Seelos is to begin an in-vivo study delivering SLS-007 by an Adeno-Associated Virus (AAV) vector making the program Seelos’ second gene therapy approach for Parkinson’s Disease (PD). Seelos is currently producing the viral vectors and preparing animals for this study. Data to determine delivery and target engagement is expected in the second half of this year."

Preclinical • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease • Rare Diseases

Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007 (GlobeNewswire, Seelos Therapeutics, Inc.) - "Seelos Therapeutics, Inc...announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos' U.S. patent application (16/311,593) covering SLS-007, which Seelos is studying in Parkinson’s disease (PD)....Seelos is currently producing adeno-associated virus (AAV) viral vectors and preparing animals for pre-clinical studies."

Patent • Preclinical

Newly added product (GlobeNewswire) - Preclinical, Parkinson's Disease

Pipeline update